CIPLA:NSE:NSE-Cipla Limited (INR)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 1409.15

Change

0.00 (0.00)%

Market Cap

USD 1,137.94B

Volume

0.70M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-28 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
ABBOTINDIA:NSE Abbott India Limited

N/A

USD 568.26B
GLAXO:NSE GlaxoSmithKline Pharmaceutical..

-4.90 (-0.25%)

USD 354.96B
GLAND:NSE Gland Pharma Limited

+1.10 (+0.06%)

USD 281.66B
SANOFI:NSE Sanofi India Limited

-2.90 (-0.04%)

USD 198.62B
PFIZER:NSE Pfizer Limited

-32.50 (-0.75%)

USD 192.64B
MARKSANS:NSE Marksans Pharma Limited

+2.65 (+1.70%)

USD 75.20B
TTKHLTCARE:NSE TTK Healthcare Limited

+9.40 (+0.62%)

USD 21.43B
SMSPHARMA:NSE SMS Pharmaceuticals Limited

+3.65 (+1.82%)

USD 17.01B
NGLFINE:NSE NGL Fine-Chem Limited

+21.60 (+0.93%)

USD 14.02B
KOPRAN:NSE Kopran Limited

+8.90 (+3.73%)

USD 12.05B

ETFs Containing CIPLA:NSE

MEE:CA Mackenzie Maximum Diversi.. 1.18 % 0.62 %

-0.01 (1.10%)

CAD 0.07B
DGRE WisdomTree Emerging Marke.. 0.79 % 0.32 %

+0.06 (+1.10%)

USD 0.13B
GLIN VanEck India Growth Leade.. 0.00 % 0.00 %

+0.52 (+1.10%)

USD 0.13B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.64% 64% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.64% 64% D 64% D
Trailing 12 Months  
Capital Gain 55.18% 55% F 56% F
Dividend Return 0.94% 78% C+ 54% F
Total Return 56.12% 55% F 56% F
Trailing 5 Years  
Capital Gain 149.41% 56% F 52% F
Dividend Return 3.81% 25% F 39% F
Total Return 153.21% 56% F 52% F
Average Annual (5 Year Horizon)  
Capital Gain 27.93% 64% D 47% F
Dividend Return 28.41% 64% D 47% F
Total Return 0.47% 33% F 41% F
Risk Return Profile  
Volatility (Standard Deviation) 27.68% 55% F 80% B-
Risk Adjusted Return 102.61% 91% A- 94% A
Market Capitalization 1,137.94B 100% F 96% N/A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.